Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical radiopharmaceutical company developing targeted cancer drugs based on its proprietary Phospholipid Drug Conjugate (PDC) platform. The CLRB news feed on Stock Titan aggregates company announcements, scientific presentations and regulatory updates that reflect the progress of this oncology pipeline.
Investors and researchers following Cellectar’s news can track developments around its lead asset, iopofosine I 131, including data from the CLOVER WaM Phase 2b study in Waldenstrom’s macroglobulinemia, the CLOVER‑2 pediatric high‑grade glioma program, and investigator‑initiated work in head and neck cancer. News items also cover FDA designations such as Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease and Fast Track, as well as EMA PRIME and orphan designations and feedback from the EMA’s Scientific Advice Working Party on a potential Conditional Marketing Authorization filing in Europe.
The CLRB news stream highlights updates on Auger‑ and alpha‑emitting candidates CLR 121125 (CLR 125) and CLR 121225 (CLR 225), including preclinical data in triple‑negative breast cancer and pancreatic ductal adenocarcinoma, clinical trial planning, and supply agreements for key radioisotopes like actinium‑225 and astatine‑211. Financial results, capital raises, warrant transactions, and reverse stock split actions reported in SEC‑linked press releases provide additional context on how the company funds its development plans.
By monitoring this page, users can review historical and ongoing disclosures about Cellectar’s clinical results, regulatory interactions, partnerships and financing activities, all drawn from company-issued news and related filings.
Cellectar Biosciences (NASDAQ: CLRB) has announced a virtual poster presentation at the ASCO Annual Meeting from June 4-8, 2021, detailing findings from its Phase 2a study of CLR 131 in Waldenstrom’s macroglobulinemia (WM). The presentation will highlight results from six patients. Management will host a KOL call with Dr. Sikandar Ailawadhi, the lead investigator, on June 4 at 10:00 am. CLR 131 targets cancer cells using the company’s Phospholipid Drug Conjugate (PDC) delivery platform and is part of a pivotal trial aimed at understanding treatment responses in WM patients.
On May 14, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will be available for one-on-one meetings and will host an on-demand presentation for registered participants. Cellectar is focused on developing cancer-targeted therapies using its proprietary Phospholipid Drug Conjugate™ delivery platform. The company’s product pipeline includes CLR 131 and other preclinical PDC programs aimed at enhancing treatment efficacy and safety for cancer patients.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced a pivotal study initiation of CLR 131 for Waldenstrom’s macroglobulinemia, titled CLOVER-WaM, aiming to enroll 50 patients. The study is aligned with FDA feedback and focuses on a major response rate.
The company received European Orphan Drug Designation for CLR 131, granting 10 years of market exclusivity. As of March 31, 2021, Cellectar holds approximately $54 million in cash, supporting operations into Q3 2023. Q1 net loss increased to $6.4 million, or $0.13 per share, compared to a loss of $4.0 million, or $0.42 per share, last year.
Cellectar Biosciences (NASDAQ: CLRB) announced the grant of a new patent titled "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by patent authorities in Eurasia, Australia, and Mexico. This patent provides protection for their phospholipid-ether (PLE) analogs used in combination with various small molecule chemotherapies. CEO James Caruso highlighted the patent's role in enhancing their phospholipid drug conjugate (PDC) platform, aimed at improving drug efficacy and safety in cancer treatment. Their lead candidate, CLR 131, is in pivotal clinical studies for hematologic cancers.
On March 11, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that its CEO, James Caruso, will present at two upcoming conferences. The Oppenheimer 31st Annual Healthcare Conference is scheduled for March 16, 2021, at 8:00 am ET, with opportunities for 1x1 meetings. The Maxim Group 2021 Emerging Growth Virtual Conference takes place from March 17-19, 2021. Cellectar focuses on cancer treatment drug development, particularly through its Phospholipid Drug Conjugate™ platform.
Cellectar Biosciences (NASDAQ: CLRB) announced on March 9, 2021, that the Japan Patent Office granted patent number 6832861 for its phospholipid-ether (PLE) analogs, enhancing its intellectual property portfolio. This patent secures composition of matter and use for these analogs in combination with various small molecule chemotherapeutics, bolstering their Phospholipid Drug Conjugates™ (PDCs™) franchise. Lead candidate CLR 131 continues to progress in clinical studies for both adult and pediatric cancer indications.
Cellectar Biosciences (NASDAQ: CLRB) announced participation in upcoming conferences for 1x1 meetings. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, and the Roth Capital Partners 33rd Annual Conference from March 15-17, 2021. Interested parties can schedule meetings through provided links. Cellectar focuses on developing cancer-targeting drugs using its Phospholipid Drug Conjugate™ (PDC) platform, including its lead product CLR 131, currently in pivotal trials for various cancers.
Cellectar Biosciences (NASDAQ: CLRB) reported its 2020 financial results and key developments. The company received Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s macroglobulinemia, facilitating reduced fees and market exclusivity. CLR 131 is undergoing pivotal trials for WM, with a primary endpoint focused on response rates. Cellectar successfully closed a $45 million public offering and highlighted CLR 131's potential in treating inoperable brain tumors. As of December 31, 2020, cash and cash equivalents reached $57.2 million, supporting operations for at least another 12 months.
Cellectar Biosciences (NASDAQ: CLRB), a biopharmaceutical firm focused on cancer treatment, announced that its CEO, James Caruso, will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing starting February 12, 2021, at 12:00 PM ET. Cellectar's proprietary Phospholipid Drug Conjugate™ (PDC) platform aims to improve cancer therapies, with CLR 131 currently in clinical studies targeting hematologic malignancies. Replays will be accessible on the company’s website.
Cellectar Biosciences (NASDAQ: CLRB) announced a positive opinion from the European Medicines Agency for CLR 131's orphan designation to treat Waldenstrom’s Macroglobulinemia. This designation grants significant benefits, including 10 years of market exclusivity in the EU. CLR 131 demonstrated a 100% overall response rate with durable effects after treatment. The company is advancing a pivotal trial for CLR 131 in relapsed/refractory patients.